# Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer.

> **NCT03055026** · PHASE3 · COMPLETED · sponsor: **Fadoi Foundation, Italy** · enrollment: 582 (actual)

## Conditions studied

- Prevention of Venous Thromboembolism

## Interventions

- **DRUG:** Rivaroxaban
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03055026
- **Lead sponsor:** Fadoi Foundation, Italy
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-03
- **Primary completion:** 2021-07-09
- **Final completion:** 2021-09-06
- **Target enrollment:** 582 (ACTUAL)
- **Last updated:** 2022-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03055026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03055026, "Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03055026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*